Vaxart (NASDAQ:VXRT) Raised to Buy at Wall Street Zen

Vaxart (NASDAQ:VXRT) was upgraded by equities researchers at Wall Street Zen to a “buy” rating in a report issued on Friday.

Vaxart Price Performance

Shares of NASDAQ VXRT opened at $0.67 on Friday. The stock has a market capitalization of $161.08 million, a price-to-earnings ratio of -2.48 and a beta of 0.95. The firm’s 50 day simple moving average is $0.43 and its 200-day simple moving average is $0.39. Vaxart has a 12 month low of $0.26 and a 12 month high of $0.84.

Hedge Funds Weigh In On Vaxart

A number of large investors have recently bought and sold shares of VXRT. Marshall Wace LLP purchased a new position in Vaxart during the second quarter worth approximately $794,000. Jones Financial Companies Lllp increased its position in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 478,111 shares in the last quarter. Raymond James Financial Inc. raised its stake in shares of Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after buying an additional 34,075 shares during the period. Invesco Ltd. lifted its position in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 70,568 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in Vaxart in the 1st quarter valued at $31,000. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.